tbuckley/cabot-search huggingface dataset:
Enhancing preventive and therapeutic cancer vaccine efficacy through biotherapeutic ligand-associated extracellular vesicles
Authors: Tamer Kahraman, Gozde Gucluler Akpinar, Muzaffer Yildirim, Pia Larssen, Banu Bayyurt-Kocabas, Fuat C Yagci, Arda Gursel, Begum Han Horuluoglu, Volkan Yazar, Ihsan Cihan Ayanoglu, Tugce Canavar Yildirim, Irem Evcili, Ismail C Yilmaz, Maria Eldh, Susanne Gabrielsson, Ulku Guler, Bekir Salih, Mayda Gursel, Ihsan Gursel
Journal: Journal of Controlled Release (2024)
Guidance for unbiased predictive information for healthcare decision-making and equity (GUIDE): considerations when race may be a prognostic factor
Authors: Keren Ladin, John Cuddeback, O. Kenrik Duru, Sharad Goel, William Harvey, Jinny G. Park, Jessica K. Paulus, Joyce Sackey, Richard Sharp, Ewout Steyerberg, Berk Ustun, David van Klaveren, Saul N. Weingart, David M. Kent
Journal: npj Digital Medicine (2024)

Clinical prediction models (CPMs) are tools that compute the risk of an outcome given a set of patient characteristics and are routinely used to inform patients, guide treatment decision-making, and resource allocation. Although much hope has been placed on CPMs to mitigate human biases, CPMs may potentially contribute to racial disparities in decision-making and resource allocation. While some policymakers, professional organizations, and scholars have called for eliminating race as a variable from CPMs, others raise concerns that excluding race may exacerbate healthcare disparities and this controversy remains unresolved. The Guidance for Unbiased predictive Information for healthcare Decision-making and Equity (GUIDE) provides expert guidelines for model developers and health system administrators on the transparent use of race in CPMs and mitigation of algorithmic bias across contexts developed through a 5-round, modified Delphi process from a diverse 14-person technical expert panel (TEP). Deliberations affirmed that race is a social construct and that the goals of prediction are distinct from those of causal inference, and emphasized: the importance of decisional context (e.g., shared decision-making versus healthcare rationing); the conflicting nature of different anti-discrimination principles (e.g., anticlassification versus antisubordination principles); and the importance of identifying and balancing trade-offs in achieving equity-related goals with race-aware versus race-unaware CPMs for conditions where racial identity is prognostically informative. The GUIDE, comprising 31 key items in the development and use of CPMs in healthcare, outlines foundational principles, distinguishes between bias and fairness, and offers guidance for examining subgroup invalidity and using race as a variable in CPMs. This GUIDE presents a living document that supports appraisal and reporting of bias in CPMs to support best practice in CPM development and use.
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
Authors: Antonio D'Alessio, Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Vincent Yip, Sarah Slater, Claudia Angela Maria Fulgenzi, Ciro Celsa, Giulia Francesca Manfredi, Madhava Pai, Robert D Goldin, Stephen C Ward, Maria Isabel Fiel, Daniel H Shu, Yung-Yeh Su, Alessio Cortellini, Marina Baretti, Robert Anders, Mark Yarchoan, Chiun Hsu, Thomas U Marron, David J Pinato
Journal: The Lancet Oncology (2024)
Biologically informed deep neural networks provide quantitative assessment of intratumoral heterogeneity in post treatment glioblastoma
Authors: Hairong Wang, Michael G. Argenziano, Hyunsoo Yoon, Deborah Boyett, Akshay Save, Petros Petridis, William Savage, Pamela Jackson, Andrea Hawkins-Daarud, Nhan Tran, Leland Hu, Kyle W. Singleton, Lisa Paulson, Osama Al Dalahmah, Jeffrey N. Bruce, Jack Grinband, Kristin R. Swanson, Peter Canoll, Jing Li
Journal: npj Digital Medicine (2024)

Intratumoral heterogeneity poses a significant challenge to the diagnosis and treatment of recurrent glioblastoma. This study addresses the need for non-invasive approaches to map heterogeneous landscape of histopathological alterations throughout the entire lesion for each patient. We developed BioNet, a biologically-informed neural network, to predict regional distributions of two primary tissue-specific gene modules: proliferating tumor (Pro) and reactive/inflammatory cells (Inf). BioNet significantly outperforms existing methods (p < 2e-26). In cross-validation, BioNet achieved AUCs of 0.80 (Pro) and 0.81 (Inf), with accuracies of 80% and 75%, respectively. In blind tests, BioNet achieved AUCs of 0.80 (Pro) and 0.76 (Inf), with accuracies of 81% and 74%. Competing methods had AUCs lower or around 0.6 and accuracies lower or around 70%. BioNet's voxel-level prediction maps reveal intratumoral heterogeneity, potentially improving biopsy targeting and treatment evaluation. This non-invasive approach facilitates regular monitoring and timely therapeutic adjustments, highlighting the role of ML in precision medicine.
The German Epidemiological Hemodialysis Itch Study (GEHIS) – 10-year follow-up of pruritus and health-related quality of life in hemodialysis patients
Authors: Philipp Bentz, Mustafa Kaplan, Lara Simontowsky, Elke Weisshaar
Journal: British Journal of Dermatology (2024)

Chronic pruritus (CP) in hemodialysis (HD) patients is a difficult to control phenomenon. While some drugs like difelikefalin showed promising results in a reduction of CP, others failed. GEHIS (German Epidemiological Hemodialysis Itch Study) is a representative, prospective cross-sectional observational cohort study of 860 HD patients started in 2013. It addresses prevalence and associated factors of CP in HD patients such as health-related quality of life (HRQOL).
Levelling up outcomes in atopic dermatitis through personalized dosing of upadacitinib
Authors: John S Barbieri
Journal: British Journal of Dermatology (2024)

Journal Article Accepted manuscript Levelling up outcomes in atopic dermatitis through personalized dosing of upadacitinib Get access John S Barbieri John S Barbieri Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA Email:jbarbieri@bwh.harvard.edu https://orcid.org/0000-0002-5467-4102 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae410, https://doi.org/10.1093/bjd/ljae410 Published: 19 October 2024 Article history Received: 16 October 2024 Accepted: 18 October 2024 Published: 19 October 2024
Basosquamous Carcinoma: A Survey Study on Current Management in the UK
Authors: Aparna Potluru, Pick N Woo, Daryl Teo, Michael V McKiernan
Journal: British Journal of Dermatology (2024)

Basosquamous carcinoma (BSC) is a rare, aggressive non-melanoma skin cancer with overlapping features of basal cell carcinoma and squamous cell carcinoma, often requiring histopathological analysis for accurate diagnosis. Our study surveyed UK dermatologists on their management practices for BSC, revealing significant variability in disease categorisation, treatment approaches, and follow-up protocols, with a noted lack of standardised guidelines. The findings underscore the need for prospective studies and the development of treatment guidelines to improve the management of BSC.
Treatment for atopic dermatitis with JAK Inhibitors-useful recommendations from expert opinions
Authors: Laura B von Kobyletzki, Åke Svensson
Journal: British Journal of Dermatology (2024)

Journal Article Accepted manuscript Treatment for atopic dermatitis with JAK Inhibitors-useful recommendations from expert opinions Get access Laura B von Kobyletzki, Laura B von Kobyletzki Orebro University, Örebro, SwedenOccupational and Environmental Dermatology, Lund University Faculty of Medicine, Malmö, Sweden Correspondence: Laura B. von Kobyletzki, Email:laura.von_kobyletzki@med.lu.se Search for other works by this author on: Oxford Academic Google Scholar Åke Svensson Åke Svensson Department of Dermatology, Malmö University Hospital, Malmö, Sweden Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae396, https://doi.org/10.1093/bjd/ljae396 Published: 19 October 2024 Article history Received: 03 October 2024 Accepted: 18 October 2024 Published: 19 October 2024
Making the Ethical Oversight of All Clinical Trials Fit for Purpose
Authors: Nancy E. Kass, Ruth R. Faden, Derek C. Angus, Stephanie R. Morain
Journal: JAMA (2024)

Importance With the increase in trials assessing comparative effectiveness of approved products and alternative care strategies, guidance is needed to ensure ethical oversight is fit for purpose for the risks, burdens, and constraints on choice this research presents. Observations US regulations governing human research emerged in response to horrific research abuses, reinforcing the view that research holds greater risks, uncertainties, and potential for abuse than clinical care, and thus protections and oversight are required for research, but not for care. The research oversight system established by these regulations has been effective, with most clinical research reviewed in advance for possible risk and burdens and for threats to autonomy and justice. For clinical research, however, it has become too much of a one-size-fits-all mechanism. As more comparative effectiveness and other research on widely used clinical interventions are conducted, research oversight should be fit for purpose for these kinds of trials, with the degree of oversight based on 2 morally relevant features of a trial. The first of these features is the degree to which risks and burdens increase or change when research is integrated into clinical care compared with what patient-participants would have experienced in care absent the research. The second is whether the activity restricts meaningful patient decision-making about care in morally important ways: (1) does the research restrict a choice or decision that patients ordinarily are or should be involved in and (2) does research participation remove from patients the ability to make a decision that may be meaningful to them, one based, at least in part, on their values, priorities, logistical or practical considerations, and the like? Whether clinical trials add risk or burden to what patients would otherwise have experienced, and whether studies restrict meaningful decisions patients would or should have had the opportunity to make, should help to determine whether clinical studies are designated as greater than vs minimal risk. Further, it is recommended that investigators and oversight bodies consider streamlined consent procedures for research presenting minimal additional risk or burden and that does not constrain meaningful patient decisions, rather than assuming that waiving all consent requirements is the only alternative. Conclusions and Relevance Ethical oversight of clinical research must be fit for purpose—with greater oversight for studies with greater risks, uncertainties, and impacts on meaningful patient decisions—and more streamlined oversight for other types of research.
The 2024 Revision to the Declaration of Helsinki
Authors: Kirsten Bibbins-Domingo, Linda Brubaker, Greg Curfman
Journal: JAMA (2024)

Andreas Alois Reis, MD, MSc; Ross Upshur, MA, MD, MSc; Keymanthri Moodley, MBChB, MMed (Fam Med), MPhil, MBA, DPhil
Comparing anti-tau antibodies under clinical trials and their epitopes on tau pathologies
Authors: Ha-Lim Song, Min-Seok Kim, Woo-Young Cho, Ye-Seul Yoo, Jae-You Kim, Tae-Wook Kim, Hyori Kim, Dong-Hou Kim, Seung-Yong Yoon
Journal: Molecular Neurodegeneration (2024)
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
Authors: Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, Lucie Oberic, Olivier Chinot, Franck Morschhauser, Frédéric Peyrade, Roch Houot, Khê Hoang-Xuan, Hervé Ghesquieres, Carole Soussain
Journal: Journal of Hematology & Oncology (2024)
Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers
Authors: Martina Sollini, Jeremie Calais, Arturo Chiti, Louise Emmett, Stefano Fanti, Wolfgang Fendler, Ken Herrmann, Thomas A Hope, Oliver Sartor, Brian Shuch, Scott Tagawa, Michael S Hofman
Journal: European Urology (2024)
Dimeric natural product panepocyclinol A inhibits STAT3 via di-covalent modification
Authors: Li Li, Yuezhou Wang, Yiqiu Wang, Xiaoyang Li, Qihong Deng, Fei Gao, Wenhua Lian, Yunzhan Li, Fu Gui, Yanling Wei, Su-Jie Zhu, Cai-Hong Yun, Lei Zhang, Zhiyu Hu, Qingyan Xu, Xiaobing Wu, Lanfen Chen, Dawang Zhou, Jianming Zhang, Fei Xia, Xianming Deng
Journal: Acta Pharmaceutica Sinica B (2024)

Homo- or heterodimeric compounds that affect dimeric protein function through interaction between monomeric moieties and protein subunits can serve as valuable sources of potent and selective drug candidates. Here, we screened an in-house dimeric natural product collection, and panepocyclinol A (PecA) emerged as a selective and potent STAT3 inhibitor with profound anti-tumor efficacy. Through cross-linking C712/C718 residues in separate STAT3 monomers with two distinct Michael receptors, PecA inhibits STAT3 DNA binding affinity and transcription activity. Molecular dynamics simulation reveals the key conformation changes of STAT3 dimers upon the di-covalent binding with PecA that abolishes its DNA interactions. Furthermore, PecA exhibits high efficacy against anaplastic large T cell lymphoma in vitro and in vivo, especially those with constitutively activated STAT3 or STAT3Y640F. In summary, our study describes a distinct and effective di-covalent modification for the dimeric compound PecA to disrupt STAT3 function.
An unexpected role of neurite outgrowth inhibitor A as regulator of tooth enamel formation
Authors: Pierfrancesco Pagella, Chai Foong Lai, Laurence Pirenne, Claudio Cantù, Martin E. Schwab, Thimios A. Mitsiadis
Journal: International Journal of Oral Science (2024)

Abstract Neurite outgrowth inhibitor A (Nogo-A) is a major player in neural development and regeneration and the target of clinical trials aiming at promoting the regeneration of the central nervous system upon traumatic and ischemic injury. In this work, we investigated the functions of Nogo-A during tooth development to determine its role in dental physiology and pathology. Using immunohistochemistry and in situ hybridization techniques, we showed that Nogo-A is highly expressed in the developing mouse teeth and, most specifically, in the ameloblasts that are responsible for the formation of enamel. Using both Nogo-A knockout and K14-Cre;Nogo-A fl/fl transgenic mice, we showed that Nogo-A deletion in the dental epithelium leads to the formation of defective enamel. This phenotype is associated with overexpression of a set of specific genes involved in ameloblast differentiation and enamel matrix production, such as amelogenin , ameloblastin and enamelin . By characterising the interactome of Nogo-A in the dental epithelium of wild-type and mutant animals, we found that Nogo-A directly interacts with molecules important for regulating gene expression, and its deletion disturbs their cellular localisation. Furthermore, we demonstrated that inhibition of the intracellular, but not cell-surface, Nogo-A is responsible for gene expression modulation in ameloblasts. Taken together, these results reveal an unexpected function for Nogo-A in tooth enamel formation by regulating gene expression and cytodifferentiation events.
Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomised, multicentre, open-label, superiority clinical trial
Authors: Julia Laporte-Amargos, Francisco Carmona-Torre, Maria Huguet, Pedro Puerta-Alcalde, Raul Rigo-Bonnin, Marta Ulldemolins, Montserrat Arnan, Jose Luis Del Pozo, Anna Torrent, Carolina Garcia-Vidal, Natàlia Pallarès, Cristian Tebé, Carme Muñoz, Fe Tubau, Ariadna Padullés, Ana-Maria Sureda, Jordi Carratalà, Carlota Gudiol
Journal: Clinical Microbiology and Infection (2024)

The efficacy of extended infusions (EI) of β-lactam antibiotics for optimising outcomes in febrile neutropenia is unclear. We assessed whether the administration of β-lactams was more effective in EI than in intermittent infusion (II) for the treatment of febrile neutropenia.
Poliovirus circulation in the WHO European region, 2015–2022: a review of data from WHO's three core poliovirus surveillance systems
Authors: Thea K Fischer, Caroline K Johannesen, Kimberley S M Benschop, Natasa Berginc, Eugene V Saxentoff, Shahin Huseynov, José E Hagan, Heli Harvala
Journal: The Lancet Regional Health - Europe (2024)
3D printing incorporating gold nanozymes with mesenchymal stem cell-derived hepatic spheroids for acute liver failure treatment
Authors: Yuanyuan Jin, Jiabin Zhang, Xiaodie Chen, Fenfang Li, Tiantian Xue, Ke Yi, Yanteng Xu, Haixia Wang, Yeh-Hsing Lao, Hon Fai Chan, Dan Shao, Mingqiang Li, Yu Tao
Journal: Biomaterials (2024)
Autogenous platelet concentrates for treatment of intrabony defects—A systematic review with meta‐analysis
Authors: Richard J. Miron, Vittorio Moraschini, Nathan Estrin, Jamil Awad Shibli, Raluca Cosgarea, Karin Jepsen, Pia‐Merete Jervøe‐Storm, Hom‐Lay Wang, Anton Sculean, Søren Jepsen
Journal: Periodontology 2000 (2024)

Abstract To provide an overview of the use of autogenous platelet concentrates (APCs) in periodontal regeneration and to conduct a systematic review (SR) of the treatment outcomes of periodontal intrabony defects by using platelet‐rich fibrin (PRF) compared with other commonly utilized modalities. The eligibility criteria comprised randomized controlled trials (RCTs) comparing the clinical outcomes of PRF with that of other modalities. Studies were classified into 21 categories and into five different groups as follows: Group I (1) open flap debridement (OFD) alone versus OFD/PRF, (2) OFD versus Titanium‐PRF (T‐PRF) Group II, (3) Comparative PRF protocols (PRF vs. T‐PRF), Group III (Comparative Studies to PRF): (4) OFD/PRP versus OFD/PRF, (5) OFD/bone graft(BG)/PRGF versus OFD/BG/PRF, (6) OFD/EMD versus OFD/PRF, (7) OFD/BG/EMD versus OFD/BG/PRF, (8) OFD/collagen membrane (CM) versus OFD/PRF, (9) OFD/BG/BM versus OFD/BG/PRF, (10) OFD/BG versus OFD/PRF, Group IV (Addition of PRF to treatment groups) (11) OFD/BG versus OFD/BG/PRF, (12) OFD/GTR versus OFD/GTR + PRF (13) OFD/EMD versus OFD/EMD/PRF (14) OFD/BG/BM versus OFD/BG/BM/PRF, Group V (Addition of Biomaterial/Biomolecule to PRF): OFD/PRF versus … (15) OFD/PRF/BG, (16) OFD/PRF/antibiotic, (17) OFD/PRF/Metformin, (18) OFD/PRF/Bisphosphonates, (19) OFD/PRF/Statins, (20) OFD/BG/PRF versus OFD/BG/PRF/Statins, and (21) OFD/PRF/low‐level laser therapy (LLLT). Weighted means and forest plots were calculated for probing pocket depth (PPD), clinical attachment level (CAL), and radiographic bone fill (RBF). From 596 records identified, 55 RCTs were included. Group I: The use of OFD/PRF statistically significantly reduced PPD and improved CAL and RBF when compared to OFD. Group II: A significant difference between various PRF protocols was only observed for PPD. Group III: No significant advantage was found when comparing OFD/PRF to the following groups: OFD/PRP, OFD/EMD, OFD/BM, or OFD/BG. Group IV: The addition of PRF to OFD/BG led to significant improvements in PPD, CAL and RBF compared with OFD/BG alone. Group V: The addition of either a BG as well as three of the following biomolecules (metformin, bisphosphonates, and statins) to OFD/PRF led to statistically significant improvements in PPD, CAL, and/or RBF when compared to OFD/PRF alone. The use of PRF significantly improved clinical outcomes in intrabony defects when compared to OFD alone. Similar results were observed when OFD/PRF was compared with OFD/BG, OFD/EMD, OFD/PRP, and OFD/BM. The addition of PRF to a bone grafting material as well as the addition of various small biomolecules to PRF may offer additional clinical advantages, thus warranting further investigations. Future research investigating various protocols of PRF, longer‐term outcomes, as well as PRF at the human histological level remains needed.
Anti irradiation nanoparticles shelter immune organ from radio-damage via preventing the IKK/IκB/NF-κB activation
Authors: Shigao Huang, Min Xu, Xiaojun Deng, Qingyue Da, Miaomiao Li, Hao Huang, Lina Zhao, Linlin Jing, Haibo Wang
Journal: Molecular Cancer (2024)

Normal tissue and immune organ protection are critical parts of the tumor radiation therapy process. Radiation-induced immune organ damage (RIOD) causes several side reactions by increasing oxidative stress and inflammatory responses, resulting in unsatisfactory curability in tumor radiation therapy. The aim of this study was to develop a novel and efficient anti irradiation nanoparticle and explore its mechanism of protecting splenic tissue from radiation in mice. Nanoparticles of triphenylphosphine cation NIT radicals (NPs-TPP-NIT) were prepared and used to protect the spleens of mice irradiated with X-rays. Splenic tissue histopathology and hematological parameters were investigated to evaluate the protective effect of NPs-TPP-NIT against X-ray radiation. Proteomics was used to identify differentially expressed proteins related to inflammatory factor regulation. In addition, in vitro and in vivo experiments were performed to assess the impact of NPs-TPP-NIT on radiation therapy. NPs-TPP-NIT increased superoxide dismutase, catalase, and glutathione peroxidase activity and decreased malondialdehyde levels and reactive oxygen species generation in the spleens of mice after exposure to 6.0 Gy X-ray radiation. Moreover, NPs-TPP-NIT inhibited cell apoptosis, blocked the activation of cleaved cysteine aspartic acid–specific protease/proteinase, upregulated the expression of Bcl-2, and downregulated that of Bax. We confirmed that NPs-TPP-NIT prevented the IKK/IκB/NF-κB activation induced by ionizing radiation, thereby alleviating radiation-induced splenic inflammatory damage. In addition, when used during radiotherapy for tumors in mice, NPs-TPP-NIT exhibited no significant toxicity and conferred no significant tumor protective effects. NPs-TPP-NIT prevented activation of IKK/IκB/NF-κB signaling, reduced secretion of pro-inflammatory factors, and promoted production of anti-inflammatory factors in the spleen, which exhibited radiation-induced damage repair capability without diminishing the therapeutic effect of radiation therapy. It suggests that NPs-TPP-NIT serve as a potential radioprotective drug to shelter immune organs from radiation-induced damage.
Haplotype-resolved genome assembly and resequencing analysis provide insights into genome evolution and allelic imbalance in Pinus densiflora
Authors: Min-Jeong Jang, Hye Jeong Cho, Young-Soo Park, Hye-Young Lee, Eun-Kyung Bae, Seungmee Jung, Hongshi Jin, Jongchan Woo, Eunsook Park, Seo-Jin Kim, Jin-Wook Choi, Geun Young Chae, Ji-Yoon Guk, Do Yeon Kim, Sun-Hyung Kim, Min-Jeong Kang, Hyoshin Lee, Kyeong-Seong Cheon, In Sik Kim, Yong-Min Kim, Myung-Shin Kim, Jae-Heung Ko, Kyu-Suk Kang, Doil Choi, Eung-Jun Park, Seungill Kim
Journal: Nature Genetics (2024)
TME-responsive nanoplatform for multimodal imaging-guided synergistic precision therapy of esophageal cancer via inhibiting HIF-1α signal pathway
Authors: Guodong Ren, Xuewei Wang, Zhaobo Yang, Xiaowan Li, Yingyu Ma, Liang Zhou, Lili Yan, Sufang Ma, Lihong Li, Lixia Guo, Boye Zhang, Haipeng Diao, Haojiang Wang, Bin Wang, Li Lu, Chengwu Zhang, Wen Liu
Journal: Journal of Controlled Release (2024)